Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates — Papers | ScholarIQ

Scholar IQ

Help

Try ScholarIQ free

Upload Records Snowball Search Search OpenAlex

About the database

ScholarIQanswers from OpenAlex

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

PaperCitations, authors & open-access status

2,950

Citations

2,010

Year

bronze

OA Status

IDs:DOI PMID OpenAlex

Related on ScholarIQ

Julie R. Brahmer

Theresa M. Salay

Tracee L. McMiller

Robert A. Anders